A New Application For Alogliptin / ACTOS (pioglitazone HCl)
Alogliptin (SYR-322) drug is considered to be a member of the DPP-4 inhibitors class, which are newer oral agents for the treating diabetes (type 2 diabetes). The drug was discovered by Takeda’s wholly owned subsidiary, Takeda San Diego, Inc. By the way, Takeda is also the author of the thiazolidinedione (TZD) diabetes medication. The aim of Actos drug (pioglitazone HCl) as a TZD is insulin resistance and besides it helps to control blood glucose levels.
It has been known from Takeda Pharmaceutical Company Limited (Takeda) its wholly owned subsidiary company, Takeda Global Research & Development Center, Inc. (U.S.), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Alogliptin and Actos medication (“alogliptin/ACTOS”) in a single tablet for the treatment of type 2 diabetes.
To substantiate The NDA submission there were conducted 3 clinical trials directing to reveal the efficacy and safety of this therapy for the treatment of patients with type 2 diabetes. Involving more than 2,000 patients worldwide the studies showed that alogliptin/ Actos drug provided essential improvements in glycemic control and measures of insulin resistance and beta-cell function.
Yasuchika Hasegawa, President of Takeda said that Alogliptin/ Actos diabetes would be the first type of diabetes drugs which includes a DPP-4 inhibitor and a TZD. He added that they would exert to provide alogliptin/ Actos diabetes medication available to patients and healthcare providers.
While conducting clinical trials physicians observed that Alogliptin/ Actos drug was generally well-tolerated. As for side effects there were noticed back pain, headache and cold-like symptoms.
